Trial Profile
A Phase 2, Double-blind, Randomized Safety And Efficacy Study Of Glasdegib (Pf-04449913) Versus Placebo In Patients With Myelofibrosis Previously Treated With Ruxolitinib
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 21 Dec 2021
Price :
$35
*
At a glance
- Drugs Glasdegib (Primary)
- Indications Myelofibrosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 02 Apr 2018 Status changed from recruiting to discontinued.
- 12 Dec 2017 Results of the single arm lead-in cohort (n=21) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 27 Oct 2017 Planned End Date changed from 24 Dec 2017 to 1 Dec 2017.